• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: Bausch + Lomb AMVISC PLUS Viscosurgical Device; Aid, Surgical, Viscoelastic

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

Bausch + Lomb AMVISC PLUS Viscosurgical Device; Aid, Surgical, Viscoelastic Back to Search Results
Model Number 60081L
Medical Device Problem Code Insufficient Device Problem Information (3190)
Health Effect - Clinical Codes Endophthalmitis (1835); Vitreous Floaters (1866); Hypopyon (1913); Loss of Vision (2139); Eye Pain (4467)
Date of Event 02/21/2026
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Investigation of this event is in progress.A follow-up report will be submitted upon completion of investigation.
 
Event or Problem Description
It was reported that 4 days after implantation of an intraocular lens (iol) in the left eye (os), the patient presented complaining of vision loss and eye pain.Slit lamp examination identified a fibrin reaction with hypopyon.Based on the findings the surgeon concluded the cause as endophthalmitis.Two days later, the patient was evaluated by a retina specialist who noted the view of posterior segment was limited due to vitreous opacity.A vitreous tap was performed, and an injection of vancomycin and ceftazidime was administered.The patient's best corrected visual acuity (bcva) decreased to hand motion.In the implanting surgeon's opinion, the most likely cause of the event could not be determined.The patient¿s outcome is unknown, as they have not returned for follow-up and cannot be reached.The following medications were prescribed for use at home post-operatively: prednisolone 1%: 1 gtt qid x 2 weeks, then tid x 2 weeks (total duration: 1 month), ofloxacin 0.3%: 1 gtt qid x 7 days, ketorolac 0.5%: 1 gtt qid x 2 weeks, then tid x 2 weeks (total duration: 1 month).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AMVISC PLUS Viscosurgical Device
Common Device Name
Aid, Surgical, Viscoelastic
Manufacturer (Section D)
Bausch + Lomb
1400 north goodman street
rochester NY 14609
Manufacturer (Section G)
Lifecore Biomedical
3515 lyman blvd.
chaska MN 55318
Manufacturer Contact
shayan habibi
21 north park place blvd.
clearwater, FL 33759
+1(727)724-6600
MDR Report Key25550059
Report Number0001313525-2026-00072
Device Sequence Number5585279
Product Code LZP
UDI-Device Identifier00757770495672
UDI-Public(01)00757770495672(17)280229(10)031158
Combination Product (Y/N)N
Initial Reporter StateCO
Initial Reporter CountryUS
PMA/510(K) Number
P810025
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source Health Professional,User Facility
Initial Reporter Occupation Physician
Type of Report Initial,Followup
Report Date (Section B) 08/24/2026
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Model Number60081L
Device Lot Number031158
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 05/20/2026
Supplement Date Received by ManufacturerNot provided
Initial Report FDA Received Date06/18/2026
Supplement Report FDA Received Date08/24/2026
Was Device Evaluated by Manufacturer? (Y/N) No
Date Device Manufactured03/30/2025
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
AKREOS AO IOL, VIS100 INJECTOR, ALCON BSS; AKREOS AO IOL, VIS100 INJECTOR, ALCON BSS.
Outcome Attributed to Adverse Event Required Intervention;
Patient Age66 YR
Patient SexMale
-
-